Compound reference
BPC-157
Also known as Body Protection Compound 157
A synthetic gastric pentadecapeptide with a deep preclinical tissue-repair record, very little controlled human evidence, and an unapproved, prohibited regulatory status.
- CAS
- 137525-51-0
- Formula
- C62H98N16O22
- Molar mass
- 1419.5 g/mol
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Half-life
- Under 30 min (IV, animal models); not established in humans
Research peptide; not FDA-approved as a drug, and clinical claims should be avoided unless source-backed.
Mode of action
BPC-157 is a synthetic, stable pentadecapeptide derived from a sequence in human gastric juice. Its proposed actions are pleiotropic and cytoprotective rather than tied to a single receptor, and the most consistent thread across the literature is the nitric oxide (NO) system.
In an isolated rat-aorta preparation, BPC-157 produced endothelium-dependent vasorelaxation by activating the Src–caveolin-1–eNOS cascade, freeing eNOS to make more NO. Musculoskeletal reviews extend the proposed signalling to VEGFR2 and Akt–eNOS, ERK1/2 engagement, and upregulation of cytoprotective growth factors — together driving the angiogenesis and fibroblast activation that would matter most in poorly vascularised tissue like tendon and ligament. A separate strand shows BPC-157 sensitising connective-tissue cells to growth hormone: in primary rat tendon fibroblasts it raised growth hormone receptor expression and amplified the proliferative response to GH, rather than acting as a direct mitogen.
Every one of these mechanisms comes from animal or ex vivo systems. None has been confirmed in humans.
Main intended effect
BPC-157 is studied chiefly to accelerate repair of poorly vascularised soft tissue — tendon, ligament, and muscle — and to protect and heal gastrointestinal mucosa. It is best read as an investigational tissue-repair peptide, not a treatment with a defined, approved indication.
Areas of interest
The heaviest interest is orthopaedic and sports-medicine recovery, where preclinical models span tendon, ligament, muscle, and bone. Gastrointestinal use is the other major thread, with animal work in colitis and ulcerative colitis — the indication in which the compound was taken furthest clinically, tested as PL-14736 — plus broader "brain–gut axis" claims. Public attention has run well ahead of the evidence: investigative reporting describes BPC-157 spreading through gray-market and "research-only" channels despite the near-absence of human data.
Evidence for intended effects
The preclinical record is large and the controlled human record is close to empty. That gap is the central fact about BPC-157.
On the preclinical side the signals are reproducible. A 2025 systematic review in orthopaedic sports medicine screened 36 studies (35 animal, 1 clinical) and found consistent accelerated repair, reduced inflammation, and improved biomechanics; a broad wound-healing review documents activity across skin, muscle, tendon, ligament, bone, nerve, gut, vessel, and cornea models.
Human evidence is minimal and almost entirely uncontrolled. The only completed controlled trial is a Phase 1 study of oral BPC-157 in 42 healthy volunteers, built to read safety and pharmacokinetics — not efficacy. Around it sit a single embedded case report, a retrospective intra-articular knee-pain series (17 patients, no placebo or blinding), and a two-person intravenous safety pilot. A randomised, double-blind, placebo-controlled Phase 2 trial in acute hamstring strain (NCT07437547) is the first prospective efficacy test, but it has not reported. Independent reviews land on the same verdict: fewer than 30 subjects across uncontrolled pilots, no completed Phase 2, and a recommendation to treat BPC-157 as strictly investigational until randomised trials read out.
| Domain | What has been studied | Highest tier so far |
|---|---|---|
| Tendon / ligament / muscle | Cell + rodent repair models; 1 case report | Preclinical (Phase 2 RCT ongoing) |
| Gastrointestinal | Rodent colitis / IBD models; early PL-14736 work | Preclinical / early-phase |
| Vascular & cytoprotection | Ex vivo aorta, ischaemia–reperfusion, NO pathway | Preclinical |
| Pharmacokinetics & safety | Rat + dog ADME; oral Phase 1 and IV pilot in humans | Phase 1 (safety / PK) |
Studied amounts (literature dosing context)
There is no established or approved human dose. A 2026 pharmaceutical-science review argues this is the real barrier to translation: no validated formulation, no characterised human pharmacokinetics, and an unexplained mismatch between the peptide's gastric-juice stability and its sub-30-minute plasma half-life in animals. Animal ADME work in rats and dogs found rapid clearance and low intramuscular bioavailability.
The amounts that appear in human studies are study facts, not recommendations: the oral Phase 1 used 1, 3, and 6 mg cohorts in healthy volunteers, and the intravenous safety pilot gave 10 mg then 20 mg to two participants. This page does not provide dosing guidance.
Safety and regulatory status
No human safety dataset of meaningful size exists. The small pilots reported no adverse events, but are far too small to characterise risk. Reviews raise theoretical concerns that follow directly from the mechanism — pro-angiogenic activity that could in principle support tumour growth, and nitric-oxide- or proline-metabolite-related effects — none established, none ruled out.
The regulatory picture is unambiguous. BPC-157 has no approved drug application in any jurisdiction. The FDA placed it in interim Category 2 (significant safety risks) in 2023, barring 503A pharmacies from compounding it. WADA lists it under class S0 (non-approved substances), prohibited at all times in sport, and the US Department of Defense prohibits it. Health Canada and provincial regulators have warned against injecting it and seized unauthorised product, noting that "research use only" labelling does not exempt a product from drug law. Investigative reporting adds that most of the foundational research traces to a single group and that financial conflicts — patent ownership by the lead researcher — have not been fully disclosed.
Sources
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Systematic review published in HSS Journal (2025) examining 36 studies — 35 preclinical and 1 clinical — on BPC-157 for orthopaedic and sports medicine applications, identified via a structured literature search. Preclinical evidence across tendon, ligament, muscle, and bone models consistently demonstrated accelerated tissue repair, reduced inflammation, and enhanced biomechanical properties attributable to BPC-157's pro-angiogenic and growth-factor-modulating actions. The single included clinical study provided limited human data, and the authors emphasize that robust evidence on dosing, safety, and efficacy in human patients does not yet exist. They conclude that BPC-157 shows biological promise for musculoskeletal injury recovery but that the absence of adequate clinical trial data — combined with risks from unregulated compounding — precludes clinical recommendation at this time.
https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
Regeneration or Risk? A Narrative Review of BPC‑157 for Musculoskeletal Healing
Narrative scoping review by McGuire, Martinez, Lenz, Skinner, and Cushman (University of Utah) published in Current Reviews in Musculoskeletal Medicine (December 2025) evaluating BPC-157’s molecular mechanisms, therapeutic potential, and safety considerations in the context of musculoskeletal healing. The authors characterize BPC-157’s principal signaling actions as activation of VEGFR2 and Akt-eNOS-driven nitric oxide synthesis, ERK1/2 pathway engagement, and upregulation of cytoprotective factors, collectively promoting angiogenesis, fibroblast activation, and neuromuscular stabilization — effects considered particularly relevant for poorly vascularized tissues such as tendons and ligaments. Only three pilot human studies were identified, covering intraarticular knee pain, interstitial cystitis, and an intravenous safety/pharmacokinetics assessment; no adverse effects were reported across these studies, but sample sizes preclude safety or efficacy conclusions. The authors conclude that BPC-157 should be considered strictly investigational until well-designed randomized controlled trials establish its safety and efficacy in human patients.
https://link.springer.com/article/10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Peer-reviewed research article by Seiwerth and more than 30 co-authors (University of Zagreb) published in Frontiers in Pharmacology (2021) reviewing the wound-healing properties of stable gastric pentadecapeptide BPC-157 across an exceptionally broad range of tissue types and injury models. Skin models covered include incisional, excisional, deep burn, diabetic ulcer, alkali burn, and fistula wounds; additional tissues encompass muscle, tendon, ligament, bone, peripheral nerve, gastrointestinal tract, blood vessels, and cornea. Key mechanistic findings include rapid (within 2 minutes) upregulation of healing-associated gene expression, VEGF-driven angiogenesis, collagen maturation superior to PDGF-BB in diabetic wound contexts, and nitric oxide system modulation that maintains endothelial integrity. Clinical context is provided by BPC-157’s safe profile in ulcerative colitis and multiple sclerosis trials, although the authors acknowledge that most evidence remains preclinical and that human investigation lags behind established growth factor research.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.627533/full
Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review
Literature and patent review by Józwiak, Bauer, Kamysz, and Kleczkowska (Medical University of Gdansk and Maria Sklodowska-Curie Medical Academy, Warsaw) published in Pharmaceuticals (2025) providing a comprehensive survey of BPC-157’s biological activities, proposed mechanisms, probable toxicity, and growing patent landscape. Preclinical evidence is reviewed across wound healing and tissue injury (alkali-burn, diabetic ulcer, collagen and angiogenesis promotion), inflammatory bowel disease, and CNS applications including dopaminergic and serotonergic modulation with reported antidepressant-like properties. The authors flag theoretical safety concerns warranting further investigation: pro-angiogenic activity that could theoretically promote tumor growth, proline-metabolite-driven oxidative stress, and the risk of neurotoxicity from excessive nitric oxide elevation. They conclude that despite an extensive preclinical record, BPC-157 remains unapproved by the FDA and other global agencies due to insufficient human clinical trial data, and note it was temporarily listed on WADA’s monitoring program in 2022.
Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Literature review by Sikiric and colleagues (University of Zagreb) published in Current Medicinal Chemistry (2012; field-standard citation for this source) surveying BPC-157 (tested clinically as PL 14736) as a therapeutic candidate for inflammatory bowel disease, particularly ulcerative colitis. The authors summarize animal evidence across upper and lower GI tract models — intestinal healing, reversal of short bowel syndrome, and fistula recovery — alongside BPC-157's capacity to stimulate EGR-1-driven cytokine and growth factor expression and to interact with the nitric oxide system for endothelial protection and angiogenesis. The compound had been assessed only through Phase II clinical trials at the time of publication, with a reported safe profile in those early studies. The review concludes that the preclinical evidence base is of high significance for future IBD therapy but remains limited by the scarcity of large-scale controlled human trial data.
Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway
This study used isolated rat aortic ring preparations to characterize BPC-157's vascular effects, demonstrating concentration-dependent and endothelium-dependent vasorelaxation mediated by nitric oxide. Mechanistically, BPC-157 activated the Src kinase–Caveolin-1–eNOS signaling cascade and reduced the inhibitory interaction between caveolin-1 and eNOS, thereby releasing eNOS for enhanced NO production. This provides a molecular basis for the vasodilatory and NO-mediated effects reported in BPC-157's broader preclinical literature and offers a proposed mechanism linking the peptide to systemic nitric oxide regulation. Findings derive from an isolated ex vivo aorta preparation; vascular effects in intact animals or humans remain to be fully characterized.
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
In primary rat Achilles tendon fibroblasts, BPC-157 dose- and time-dependently upregulated growth hormone receptor (GHR) expression at both the mRNA and protein level across a range of concentrations and time points. When exogenous growth hormone was added to BPC-157-primed fibroblasts, cellular proliferation was enhanced beyond either agent alone, indicating BPC-157 sensitizes connective tissue cells to ambient GH rather than acting as a direct mitogen. This receptor-sensitization mechanism may partly explain the peptide's reported tendon and ligament repair effects in rodent injury models. All data are from primary rat fibroblast cultures; clinical translation has not been established.
Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights
This preclinical rat study evaluated the stable gastric pentadecapeptide BPC-157 in models of colitis and ischemia-reperfusion injury, examining its effects on mucosal healing, vascular recovery, and the nitric oxide system. BPC-157 administration ameliorated inflammatory lesion severity in the colitis model and attenuated ischemia-reperfusion-induced tissue damage, with effects attributed in part to modulation of nitric oxide signaling pathways. The study contributes to a body of preclinical evidence characterizing BPC-157 as a pleiotropic cytoprotective peptide active across gastrointestinal and vascular injury contexts. All findings are from rat models; no human clinical evidence was produced.
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
This study by Xu and colleagues provides the first systematic ADME characterization of BPC-157 in Sprague-Dawley rats (20–500 µg/kg intramuscular; 20 µg/kg intravenous) and beagle dogs (6–150 µg/kg intramuscular; 6 µg/kg intravenous). Both species showed rapid elimination, with intravenous half-lives under 30 minutes, intramuscular Tmax of approximately 3 minutes in rats and 6–9 minutes in dogs, and intramuscular bioavailability of 14–19% in rats and 45–51% in dogs. Plasma clearance was 50.1 ml/min/kg in rats and 90.8 ml/min/kg in dogs, and the peptide was degraded proteolytically into six metabolites, primarily eliminated via urine (15.88%) and bile (9.08%). The short half-life and low oral bioavailability represent key translational limitations; no human pharmacokinetic data exist.
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
Narrative review by Mateescu and colleagues at Victor Babeș University (Timișoara) published in Pharmaceutics (2026) that systematically evaluates the pharmaceutical science deficiencies impeding BPC-157's clinical translation despite over three decades of preclinical research. The authors document that BPC-157 possesses anomalous gastric-juice stability yet exhibits a sub-30-minute plasma half-life in preclinical models, a pharmacokinetic-pharmacodynamic disconnect that remains unexplained and uncharacterized in humans. No pharmaceutical-grade formulation, validated dosing regimen, or biopharmaceutical classification data exist, and clinical evidence derives from fewer than 30 subjects across uncontrolled pilot studies with no completed Phase II trial. The central conclusion is that the primary barrier to clinical translation is not the absence of biological activity but the absence of fundamental pharmaceutical science — characterized formulations, validated pharmacokinetics, and formal excipient compatibility assessments — without which regulatory approval pathways cannot be initiated.
PCO‑02 – Safety and Pharmacokinetics Trial
Phase 1, randomized, placebo-controlled first-in-human trial (PharmaCotherapia d.o.o.; NCT02637284) of oral BPC-157 (PCO-02 formulation) in 42 healthy volunteers. The design included single-dose cohorts (1, 3, and 6 mg) and a 14-day multiple-dose arm to assess dose escalation tolerability. Primary outcome was safety; secondary outcomes were pharmacokinetic parameters characterizing oral absorption and clearance. This study constitutes the primary controlled safety and pharmacokinetics dataset for oral BPC-157 in humans; no efficacy endpoints were evaluated in this healthy-volunteer safety study.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Retrospective chart review (Lee and Padgett) of 17 patients (16 contactable at follow-up) given intra-articular BPC-157, either alone or combined with thymosin beta-4, for various types of knee pain in a primary-care setting in Orlando, Florida. Among those receiving BPC-157 alone, 11 of 12 (91.6%) reported significant improvement; the combined peptide group showed 75% improvement; overall, 14 of 16 patients (87.5%) reported pain relief. No placebo arm, blinding, or objective outcome measures were used, making results highly susceptible to placebo effect and reporting bias. The report is hypothesis-generating only and does not establish efficacy.
Effect of BPC-157 on healing of transected Achilles tendon in rats and a case report in a human
This publication provides the only identified human-level evidence for BPC-157, consisting of a single case report of BPC-157 injection used for an ankle injury rather than a controlled trial. The report is embedded within a largely preclinical paper examining tendon healing in animals. Without blinding, a comparator group, or prospective design, the case report is hypothesis-generating only and cannot establish safety, dosing, or efficacy in humans. No controlled human trials for BPC-157 have been published to date.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
IRB-approved pilot safety study published in Alternative Therapies in Health and Medicine (2025) enrolling two healthy adults — a 58-year-old Asian male and a 68-year-old Caucasian female — who received intravenous infusions of BPC-157 (10 mg on Day 1 and 20 mg on Day 2, each diluted in 250 mL normal saline and administered over one hour). No adverse effects were reported and no measurable changes were observed in cardiac, hepatic, renal, thyroid, or glycemic biomarkers. The authors concluded that IV BPC-157 up to 20 mg was well-tolerated in this pair of participants, while noting that the two-person sample size precludes broader safety conclusions and that larger studies are required.
BPC 157 for Acute Hamstring Muscle Strain Repair (BPC‑HAMSTR)
Randomized, double-blind, placebo-controlled Phase 2 trial (NCT07437547; Hudson Biotech) evaluating subcutaneous BPC-157 in 120 participants with acute grade II hamstring muscle strain. Co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at day 14. This is the first prospective placebo-controlled human trial of BPC-157 for musculoskeletal injury; results are not yet available. The trial represents a substantial advance over the prior human case-report literature and will provide the first controlled evidence of safety and efficacy in this indication.
BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products
Consumer safety overview from Operation Supplement Safety (OPSS, 2025) classifying BPC-157 as an unapproved drug with no FDA-approved indication and no legal over-the-counter status. The DoD Prohibited Dietary Supplement Ingredients List includes BPC-157 per DoDI 6130.06, and the World Anti-Doping Agency classifies it as a prohibited substance. OPSS notes that evidence for safety and effectiveness in humans is absent — available data derive from animal models only — and that the FDA has specifically warned against compounded BPC-157 products due to safety risks and potential contamination. Products are commonly marketed as "research chemicals" with disclaimers of non-human use to circumvent regulatory oversight.
BPC-157 Bulk Drug Substance for Compounding
FDA webpage listing bulk drug substances that may present significant safety risks when used in compounding under section 503A. BPC-157 was placed in interim Category 2 — meaning it may present significant safety risks — with the listing effective September 2023. The FDA's concerns include immunogenicity risk, the presence of peptide-related impurities, incomplete characterization of the active ingredient, and the absence of adequate human safety and efficacy data. Category 2 status means 503A compounding pharmacies may not compound preparations using BPC-157 as a bulk substance. The listing reflects a risk determination only; BPC-157 has no FDA-approved drug application and is not an approved therapeutic product.
WADA Prohibited List 2026
The World Anti-Doping Agency 2026 Prohibited List, approved September 11, 2025 and effective January 1, 2026. BPC-157 is explicitly named as an example under class S0 (Non-Approved Substances), which encompasses all pharmacological substances not approved for human therapeutic use by any governmental regulatory health authority. S0 substances are prohibited at all times, both in- and out-of-competition. The S0 listing reflects the absence of any regulatory approval for BPC-157 in any jurisdiction and applies to all sports governed by the World Anti-Doping Code. An athlete who tests positive for a S0 substance faces the same sanctions as any other doping violation.
https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
Think twice before injecting peptides bought online: unauthorized products can seriously harm you
Health Canada public safety advisory published April 9, 2026 warning consumers against injecting peptides purchased online. The advisory explicitly names numerous peptides commonly available through unregulated channels, including BPC-157, CJC-1295, GHK-Cu, Ipamorelin, Melanotan I and II, MOTS-c, SS-31, TB-500, and Retatrutide, among others. Health Canada confirms that peptides are generally regulated as prescription drugs in Canada and that unauthorized products have not been assessed for safety, efficacy, or quality. Identified risks include hormonal imbalance, blood sugar dysregulation, liver or kidney damage, blood clots, tumor growth, infections, and contaminants including heavy metals and bacteria. The advisory explicitly states that "For Research Use Only" labeling does not exempt a product from Canadian drug regulations, and that lawfully authorized Canadian drugs display an eight-digit Drug Identification Number (DIN).
From Croatia to MAHA: How an unapproved drug became the next hot peptide
STAT News investigative report on BPC-157’s rapid rise in popularity, the near-total absence of human clinical data, and escalating regulatory scrutiny. The article notes that virtually all research originates from a single Croatian group (Sikiric and colleagues), with the few registered human trials involving only 2–16 participants; a 2015 clinicaltrials.gov trial submitted data then withdrew before external review. The FDA in 2023 banned compounding pharmacies from supplying BPC-157, citing "potential significant safety risks" including possible immune responses and unknown purity of gray-market sources. Experts warn that angiogenic activity could accelerate tumor growth, and that financial conflicts of interest (patent ownership by the lead researcher) have not been fully disclosed. The article concludes that BPC-157 "should not be used by humans" until rigorous clinical trials are completed.
https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/